Journal article · 2026

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, М. Є. Сабадаш, Alejo Rodríguez‐Vida, Zhentao Zhang, Vagif Atduev, Y.E. Goger, Steffen Rausch, Seok-Ho Kang, Yohann Loriot, Jens Bedke and 14 more

New England Journal of Medicine, 394(13), 1257–1269 · Published 18 February 2026 · DOI 10.1056/nejmoa2511674

View at the publisherCite this paper

In brief

“Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer” is a 2026 journal article by Christof Vulsteke and 25 co-authors, published in New England Journal of Medicine. OpenAlex counts 161 citations as of 16 November 2026, which puts it in the top 1% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
161
Most cited in
2026 (161)
Field-weighted impact
692.79
References
23
Authors
26

Abstract

BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may improve outcomes in this population. METHODS: In this phase 3, open-label trial, participants with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy were randomly assigned to perioperative (neoadjuvant… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Vulsteke, C., Adra, N., Danchaivijitr, P., Сабадаш, М. Є., Rodríguez‐Vida, A., Zhang, Z., Atduev, V., Goger, Y., Rausch, S., Kang, S.-H., Loriot, Y., Bedke, J., Galsky, M. D., O’Donnell, P. H., Amsberg, G. V., Alimohamed, N. S., Sulimka, G., Gupta, S., Paramonov, V., . . . Ullén, A. (2026). Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine, 394(13), 1257–1269. https://doi.org/10.1056/nejmoa2511674

MLA 9

Vulsteke, Christof, et al. “Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.” New England Journal of Medicine, vol. 394, no. 13, 2026, pp. 1257–1269. https://doi.org/10.1056/nejmoa2511674.

Chicago

Vulsteke, Christof, Nabil Adra, Pongwut Danchaivijitr, М. Є. Сабадаш, Alejo Rodríguez‐Vida, Zhentao Zhang, Vagif Atduev, et al. 2026. “Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.” New England Journal of Medicine 394 (13): 1257–1269. https://doi.org/10.1056/nejmoa2511674.

Harvard

Vulsteke, C. et al. (2026) ‘Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer’, New England Journal of Medicine, 394(13), pp. 1257–1269. doi:10.1056/nejmoa2511674.

IEEE

C. Vulsteke et al., “Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer,” New England Journal of Medicine, vol. 394, no. 13, pp. 1257–1269, 2026, doi: 10.1056/nejmoa2511674.

BibTeX

@article{vulsteke2026perioperative,
  title     = {{Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer}},
  author    = {Vulsteke, Christof and Adra, Nabil and Danchaivijitr, Pongwut and Сабадаш, М. Є. and Rodríguez‐Vida, Alejo and Zhang, Zhentao and Atduev, Vagif and Goger, Y.E. and Rausch, Steffen and Kang, Seok-Ho and Loriot, Yohann and Bedke, Jens and Galsky, Matthew D. and O’Donnell, Peter H. and Amsberg, Gunhild v. and Alimohamed, Nimira S. and Sulimka, Grzegorz and Gupta, Shilpa and Paramonov, V.V. and Nakane, Keita and Mihm, Michael and Meng, Changting and Huang, Caizhi David and Ramamurthy, Chethan and Moreno, Blanca Homet and Ullén, Anders},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  volume    = {394},
  number    = {13},
  pages     = {1257--1269},
  doi       = {10.1056/nejmoa2511674},
  url       = {https://doi.org/10.1056/nejmoa2511674}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments

  • muscle-invasive bladder cancer
  • enfortumab vedotin
  • pembrolizumab
  • perioperative therapy
  • neoadjuvant therapy
  • adjuvant therapy
  • antibody-drug conjugates
  • nectin-4

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Vulsteke, C., Adra, N., Danchaivijitr, P., Сабадаш, М. Є., Rodríguez‐Vida, A., Zhang, Z., Atduev, V., Goger, Y., Rausch, S., Kang, S.-H., Loriot, Y., Bedke, J., Galsky, M. D., O’Donnell, P. H., Amsberg, G. V., Alimohamed, N. S., Sulimka, G., Gupta, S., Paramonov, V., . . . Ullén, A. (2026). Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine, 394(13), 1257–1269. https://doi.org/10.1056/nejmoa2511674

How many times has this paper been cited?

161 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, М. Є. Сабадаш, Alejo Rodríguez‐Vida, Zhentao Zhang, Vagif Atduev, Y.E. Goger, Steffen Rausch, Seok-Ho Kang, Yohann Loriot, Jens Bedke and 14 more.

What is the DOI of this paper?

10.1056/nejmoa2511674, permanently at https://doi.org/10.1056/nejmoa2511674. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.